

	POLICY TITLE: Subject Screening and Enrolling
MANUAL NAME: Clinical Operations	POLICY NUMBER: CR 1.2.2 <input type="checkbox"/> Addendum to Corporate Policy <input type="checkbox"/> Form Available In I-REPP System
SECTION (as applicable): Clinical Research	POLICY OWNER: Tedd Adair, Vice President of Clinical Operations and Chief Clinical Officer
ORIGINATION DATE: 01/01/2011	FINAL APPROVAL DATE: April 30, 2016

POLICY:

When tracking the list of potential, consented, and enrolled subjects, to document the fair and unbiased screening and enrolling of subjects for each study and to ensure that enrolled subjects have easily available identification information in the event that they need to be contacted.

SCOPE:

This procedure applies to all clinical trials conducted at any IASIS facility.

DEFINITIONS:

Not Applicable

PROCEDURE:

Subject Logs:

- Every potential subject with whom an informed consent discussion is conducted is listed on a subject screening log, whether or not they agree to participate.
- Every subject who signs the informed consent form is tracked to indicate whether the subject was enrolled (i.e., randomized to treatment).
- A copy of every signed informed consent form for any subject participating in research being conducted at an IASIS facility is sent to the ICARE Office of Research.
- Every subject who is randomized to treatment is listed on a subject identification log.
- Every subject who is randomized to treatment for a study being conducted at an IASIS facility has an IASIS Patient Enrollment Notification Form completed and submitted to the ICARE Office of Research.
- The above subject screening, enrollment, and identification information is documented in one of two ways:

- 1) if the sponsor has a preferred method for tracking this information, this method is followed.
- 2) if the sponsor does not have a preferred method, the attached form is used or similar form.

Responsibility:

- The study coordinator is responsible for ensuring that all screening, enrollment and identification logs are kept up to date.
- The study coordinator is responsible for ensuring the scheduled submission of the screening and/or enrollment logs to the designated contact as instructed by the sponsor.
- The Principal Investigator or his/her designee is responsible for completing and submitting the proper Patient Enrollment Notification Form and a copy of signed Informed Consent Forms for any and all subjects participating in studies being conducted at any IASIS facility.

SUBJECT IDENTIFICATION LOG

Sponsor: _____

Protocol #: _____

#	Initials	Name	Address	Phone #'s



RESEARCH PATIENT SCHEDULING AND CHARGE FORM

- Schedule a research test or procedure
- Schedule a research component of a Standard of Care (SOC) Visit
- Schedule a SOC services for a research participant

***Use ONE form per visit**

I-CARE:		Phone:		Email:	
Name of Study:			Principal Investigator:		
ClinicalTrials.gov #:			Sub Investigator:		
Location/Facility:			IRB:		
CMS Approval	IDE No				
Research Participant Information					
Last Name:			First Name, MI:		
Date of Birth:			Subject ID:		
Health Care Provider Information					
Ordering Physician:		Study Coordinator:		Phone #/Email	
Insurance Provider Information					
Billing Commercial Payor *		<input type="checkbox"/>			
Billing Medicare *		<input type="checkbox"/>			
Billing I-CARE Contract Account		<input type="checkbox"/>			
Billing					
Test, Procedure, or Service Requested	Com.	Medicare	I-CARE	Q0 / Q1	Date of Service
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
*Claims to include Research Modifiers and/or Z codes and ClinicalTrials.gov registration number.					
Form completed by:				Date:	

REFERENCES: Food and Drug Administration

Review/Revised Date:	Title:	Description of Change or Location of Change in Document:
04/30/2016	Tedd Adair VP of Clinical Operations & CCO	Scheduled review; converted to ISO Policy Template